BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 30998989)

  • 21. A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.
    Drost M; Zonneveld JB; van Hees S; Rasmussen LJ; Hofstra RM; de Wind N
    Hum Mutat; 2012 Mar; 33(3):488-94. PubMed ID: 22102614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
    Peltomäki P
    Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of cancer susceptibility.
    Crépin M; Dieu MC; Lejeune S; Escande F; Boidin D; Porchet N; Morin G; Manouvrier S; Mathieu M; Buisine MP
    Hum Mutat; 2012 Jan; 33(1):180-8. PubMed ID: 21953887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
    Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
    Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.
    Rath A; Mishra A; Ferreira VD; Hu C; Omerza G; Kelly K; Hesse A; Reddi HV; Grady JP; Heinen CD
    Hum Mutat; 2019 Nov; 40(11):2044-2056. PubMed ID: 31237724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer Risk C (CR-C), a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency.
    Alim I; Loke J; Yam S; Templeton AS; Newcomb P; Lindor NM; Pai RK; Jenkins MA; Buchanan DD; Gallinger S; Klugman S; Ostrer H
    Genet Med; 2022 Sep; 24(9):1821-1830. PubMed ID: 35616648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors.
    Mensenkamp AR; Vogelaar IP; van Zelst-Stams WA; Goossens M; Ouchene H; Hendriks-Cornelissen SJ; Kwint MP; Hoogerbrugge N; Nagtegaal ID; Ligtenberg MJ
    Gastroenterology; 2014 Mar; 146(3):643-646.e8. PubMed ID: 24333619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UMD-MLH1/MSH2/MSH6 databases: description and analysis of genetic variations in French Lynch syndrome families.
    Grandval P; Fabre AJ; Gaildrat P; Baert-Desurmont S; Buisine MP; Ferrari A; Wang Q; Béroud C; Olschwang S
    Database (Oxford); 2013; 2013():bat036. PubMed ID: 23729658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing how reduced expression levels of the mismatch repair genes MLH1, MSH2, and MSH6 affect repair efficiency.
    Kansikas M; Kasela M; Kantelinen J; Nyström M
    Hum Mutat; 2014 Sep; 35(9):1123-7. PubMed ID: 24924810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.
    Jansen AM; Geilenkirchen MA; van Wezel T; Jagmohan-Changur SC; Ruano D; van der Klift HM; van den Akker BE; Laros JF; van Galen M; Wagner A; Letteboer TG; Gómez-García EB; Tops CM; Vasen HF; Devilee P; Hes FJ; Morreau H; Wijnen JT
    PLoS One; 2016; 11(6):e0157381. PubMed ID: 27300758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Verification of the three-step model in assessing the pathogenicity of mismatch repair gene variants.
    Kansikas M; Kariola R; Nyström M
    Hum Mutat; 2011 Jan; 32(1):107-15. PubMed ID: 21120944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive functional assessment of MLH1 variants of unknown significance.
    Borràs E; Pineda M; Brieger A; Hinrichsen I; Gómez C; Navarro M; Balmaña J; Ramón y Cajal T; Torres A; Brunet J; Blanco I; Plotz G; Lázaro C; Capellá G
    Hum Mutat; 2012 Nov; 33(11):1576-88. PubMed ID: 22736432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.
    Ziada-Bouchaar H; Sifi K; Filali T; Hammada T; Satta D; Abadi N
    Fam Cancer; 2017 Jan; 16(1):57-66. PubMed ID: 27468915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
    Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
    Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for breast cancer as an integral part of Lynch syndrome.
    Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
    Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.
    Carneiro da Silva F; Ferreira JR; Torrezan GT; Figueiredo MC; Santos ÉM; Nakagawa WT; Brianese RC; Petrolini de Oliveira L; Begnani MD; Aguiar-Junior S; Rossi BM; Ferreira Fde O; Carraro DM
    PLoS One; 2015; 10(10):e0139753. PubMed ID: 26437257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance-functional analysis reveals the pathogenic one.
    Kantelinen J; Hansen TV; Kansikas M; Krogh LN; Korhonen MK; Ollila S; Nyström M; Gerdes AM; Kariola R
    Fam Cancer; 2011 Sep; 10(3):515-20. PubMed ID: 21431882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.